TY - JOUR
T1 - Improved survival rates of patients with acral lentiginous melanoma treated with hyperthermic isolation perfusion, wide excision, and regional lymphadenectomy
AU - Fletcher, John R.
AU - White, Clifton R.
AU - Fletcher, William S.
N1 - Funding Information:
From the Division of Surgical Oncology, Oregon Health Sciences University, Portland, Oregon. Supported in part by the Grand Chapter Oregon. Order of Eastern Star, Portland, Oregon. Requests for reprints should be addressed to William S. Fletcher. MD. Division of Suroical Oncoloov L-223. Oreoon Health Sciences Universitv. 3161 SW SamJackson Pari’Road, Portlaid. Oregon 97201. Presented at the 72nd Annual Meeting of the North Pacific Surgical Association, Portland, Oregon, November 8 and 9, 1986.
Copyright:
Copyright 2014 Elsevier B.V., All rights reserved.
PY - 1986/5
Y1 - 1986/5
N2 - Twenty-three patients with extremity malignant melanoma who fit the clinical and pathologic criteria for acral lentiginous melanoma were treated in a prospective, nonrandomized trial of wide local excision, regional lymphadenectomy, and hyperthermic isolation perfusion. There were 17 patients (73.9 percent) pathologically judged to be in stage I and 6 (26.1 percent) in stage II. Three patients entered the study with regional recurrence. Delay in diagnosis of the lesions averaged almost 3 1 2 years. Increasing awareness about the occurrence of acral lentiginous melanoma may result in earlier diagnosis, increased survival rates, and cure. Life table survival analysis revealed 5 and 10 year survival rates of 75 percent and 58 percent, respectively. This supports the findings of Krementz et al [11] and suggests not only that a marked improvement in survival can be achieved through the use of hyperthermic isolation perfusion, but that the survival of patients with acral lentiginous melanoma is comparable with that of patients with other extremity malignant melanomas treated with aggressive multimodality therapy.
AB - Twenty-three patients with extremity malignant melanoma who fit the clinical and pathologic criteria for acral lentiginous melanoma were treated in a prospective, nonrandomized trial of wide local excision, regional lymphadenectomy, and hyperthermic isolation perfusion. There were 17 patients (73.9 percent) pathologically judged to be in stage I and 6 (26.1 percent) in stage II. Three patients entered the study with regional recurrence. Delay in diagnosis of the lesions averaged almost 3 1 2 years. Increasing awareness about the occurrence of acral lentiginous melanoma may result in earlier diagnosis, increased survival rates, and cure. Life table survival analysis revealed 5 and 10 year survival rates of 75 percent and 58 percent, respectively. This supports the findings of Krementz et al [11] and suggests not only that a marked improvement in survival can be achieved through the use of hyperthermic isolation perfusion, but that the survival of patients with acral lentiginous melanoma is comparable with that of patients with other extremity malignant melanomas treated with aggressive multimodality therapy.
UR - http://www.scopus.com/inward/record.url?scp=0022534747&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022534747&partnerID=8YFLogxK
U2 - 10.1016/0002-9610(86)90559-3
DO - 10.1016/0002-9610(86)90559-3
M3 - Article
C2 - 3518512
AN - SCOPUS:0022534747
SN - 0002-9610
VL - 151
SP - 593
EP - 598
JO - The American Journal of Surgery
JF - The American Journal of Surgery
IS - 5
ER -